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ABSTRACT
Background: Minimal hepatic encephalopathy (MHE) has a mild
neurocognitive impairment that includes neuropsychological and
neurophysiological alterations that can not be detected by clinical
examination. This study aims to assess the frequency and risk
factors for developing minimal hepatic encephalopathy in patients
with compensated cirrhosis. Methods: This cross sectional study
was conducted on 60 patients with compensated cirrhosis in
Zagazig University Hospital and elmatarya Teaching Hospital
from December 2017 to June 2018, diagnosis of minimal hepatic
encephalopathy was established by using mini mental status
examination test and psychometric studies, they underwent full
history, laboratory investigations and abdominal doppler
ultrasonography by professional radiologist assessing the presence
of any porto systemic shunts and measuring serum ammonia level.
Results: About 37% had MHE. Female represented 65% with
mean age 49.82 years. There is statistically significant relation
between MHE and smoking, comorbid diabetes, hypertension,
high ammonia level and portosystemic shunt. Smoking, being
single, illiterate, portosystemic shunt, comorbid diabetes and
hypertension increased risk of MHE by 4.57, 3.05, 2.31, 25.94,
3.29 and 3.55 folds. Male gender and normal ammonia level were
protective factors. There is significant relation between MHE and
age, platelet count, serum albumin, ammonia and INR. Older
patients, low platelet count and serum albumin, high ammonia
level and INR were detected among patients with MHE.
Increasing ammonia level was significant independent risk factor
for MHE. Conclusions: MHE is a prevalent condition among
patients with compensated cirrhosis with high ammonia level and
portosystemic shunts as a strong risk factors for its development.
Keywords: hepatic encephalopathy; shunt; ammonia

INTRODUCTION
inimal hepatic encephalopathy has a
moderate neurocognitive disorder that
involves
neuropsychological
and
neurophysiological changes that can not be
identified through clinical review [1]. MHE is

M
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the mildest type inside the spectrum of hepatic
encephalopathy (HE). MHE is viewed as the
initial phase of the hepatic encephalopathy
process. This causes up to 80 per cent of
cirrhosis patients [2].
MHE can be observed in patients with
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cirrhosis and in non-cirrhosis patients with
Porto systemic shunting that affecting up to
80% of patients with cirrhosis [3]. MHE has
a negative impact on day-to-day activities and
workability affects health-related quality of
life [4] impairs driving fitness[5], associated
with motor vehicle crashes[6] and predisposes
the patient to fall[7]. In addition, MHE is of
prognostic significance as it is a risk factor for
overt HE development [8] and death.
Recognizing MHE and its risk factors is
important because its treatment can improve
cognitive functions [9] and quality of life [10]
and avert progression to overt HE [11].
The initial indications for studying whether a
patient is at risk of MHE are problems of
quality of life and complaints from relatives
and caregivers. Ideally, patients at imminent
risk should be evaluated, including those with
previous episodes of HE, cirrhotic patients
and those performing risky public activities
such as bus drivers [12-13]. There is actually
no gold standard for MHE diagnosis, because
it impacts multiple cognitive functioning
pathways that do not generally deteriorate
similarly. The ISHEN (International Society
for Hepatic Encephalopathy and Nitrogen
metabolism) advises at least two different
tests for diagnosis [14]. MHE identification
methods are classified into two main types:
psychometric and neuropsychological studies
[15].
The aim of this work is to identify the
frequency and risk factors associated with
development
of
minimal
hepatic
encephalopathy
among
patients
with
compensated cirrhosis.
METHODS
The work has been carried in accordance with
The Code of Ethics of the World Medical
Association (Declaration of Helsiniki) for
studies involving humans. A written informed
consent was handled from the patient to
contribute in the study. Approval for carrying
out the work was received from the
Departments of Internal Medicine and
Clinical Biochemistry, University Hospitals
of Zagazig, after obtaining an academic
review board.
Study Design, Study Setting, and Study
Participants
Mahmoud A.,et al…
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This is a cross sectional study conducted in
elzagazig University Hospital and elmataria
teaching hospital from December 2017 to
June 2018.
Patients
included
in
the
study:
Comprehensive sample of sixty patients with
compensated cirrhosis who fulfilled the
inclusion criteria .
Inclusion criteria: Adult patients of both
genders (aged 18 to 60 years old). Serum
albumin ≥3.5gm/dl, serum INR≤ 1.7, Serum
bilirubin ≤ 2gm/dl, Absence of ascites or
HCC.
Exclusion criteria: Decompensated cirrhosis.
Patients who refuse to participate in the study
Study tools and data collection: Complete
history taking and Clinical examination were
performed for all patients.
Laboratory investigations were done to
verify eligibility of patients to be included in
the study and identify potential risk factors:
Routine investigations:, Complete blood
picture, erythrocyte sedimentation rate,
random blood glucose. Viral markers : HBS
Ag, HCV- Ab
Complete liver biochemical profile: Serum
bilirubin (total and direct), Liver enzymes
(AST and ALT), Serum albumin, total
proteins, Prothrombin time, concentration and
INR. Kidney function (Urea and Creatinine).
Blood ammonia level:
Radiological investigation: Abdominal
doppler ultrasound to assess: portal vein
diameter, presence of any porto systemic
shunts (collaterals), liver parenchyma, ascites,
splenomegaly and any other significant
sonographic data.
Mini-mental state examination to identify
MHE (occult neurosychiatric and cognitive
abnormalities) [16]: A brief 30- point
questionnaire
used
for
quantitative
measurement. of cognitive status in adults.
The total score of the test is 30. Any score
over 27 is considered normal.
Scores
between (20-26) indicate some cognitive
impairment. Scores between (10-19) indicates
moderate to severe cognitive impairment.
Scores below 10 indicate severe cognitive
impairment .
Number connection test A(NCT A)[17]: In
this test, numbers are arranged in a random
82 | P a g e
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series and must be related to each other in
their correct sequence as quickly as possible,
using pencil to draw line between them. The
test is designed to help healthy people to
perform this task in under 45 seconds (taking
in consideration his age and education level).
If the patient takes more than the given time,
MHE can be diagnosed with high sensitivity.
Case
definition
of
MHE:
Neuropsychological and neurophysiological
abnormalities that are not detectable from the
clinical evaluation usually used to identify the
presence of MHE; these include cognitive and
attention deficits, loss of inhibitory response,
loss of working memory and lack of
visuomotor coordination. Patients with
MMSE score less than 27 and more than 2
seconds above the limited time in NCT
(talking in consideration age and education
level) are included.
Statistical Analysis:
All data for windows (SPSS Inc., Chicago,
IL, USA) & MedCalc 13 for windows
(MedCalc Software bvba, Ostend, Belgium)
were gathered, tabulated and statistically
analyzed using SPSS 20.0. Using the Shapiro
Walk test the data was tested for normal
distribution. Qualitative data as frequencies
and relative percentages were symbolized.
Used for the measurement of disparity
between qualitative variables, the Chi square
method (Š2). Quantitative results as mean ±
SD (standard deviation) have been published.
Mann Whitney test was used to compare twogroup
medians
(for
nonparametric
data).Independent sample t test was used to
compare two-group information. The study of

10.21608/zumj.2020.22641.1698

conditional logistic regression has been used
to classify risk factors for the growth of MHE.
Level of P-value ≤ 0.05 is significant and p
≤0.001 is highly significant difference.
RESULTS
About 37% of the studied patients had
MHE (Table 1). Half of them were diabetic
and the same percentage were smokers. Forty
percent of them had comorbid hypertension.
About 58% and 77% of them were educated
and married. Ninety five percent had hepatitis
C. Portosystemic shunt and high ammonia
level were present in 63.3% and 88.3%. There
is statistically significant relation between
presence of MHE and all of smoking,
comorbid diabetes, hypertension, high
ammonia level and portosystemic shunt.
There is statistically non-significant relation
between MHE and either education, type of
hepatitis, being single, illiterate. Male gender
and normal ammonia level were protective
factors (Table 2)
Mean age of the studied patients was 49.82
years. There is significant relation between
MHE and all of age, platelet count, serum
albumin, ammonia and INR. Older patients,
low platelet count, low serum albumin, high
ammonia level and elevated INR were
detected among patients with MHE. On the
other hand, there is non-significant relation
between MHE and either hemoglobin level,
TLC, ALT, AT or total bilirubin (table 3).
Increased ammonia level was a significant
independent risk factor for MHE in patients
with compensated cirrhosis where it increased
the risk by 4.06 folds (table 4)

Table 1. Distribution of the studied patients according to presence of MHE
MHE
N=60
38
Absent
22
Present
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%
63.3
36.7
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Table 2. Relation between presence of MHE and the studied parameters
Total
MHE
p
N=60
Yes
No
(n=22)
(n=38)
Gender:
Male
21 (35)
4 (19)
17 (81)
0.051
Female
39 (65)
18 (46.2)
21 (53.8)
Smoking:
No
30 (50)
6 (20)
24 (80)
0.007*
Yes
30 (50)
16 (53.3)
14 (46.7)
Education:
Illiterate
25 (41.7)
12 (48)
13 (52)
0.124
Educated
35 (58.3)
10 (28.6)
25 (71.4)
Marital status:
Single
14 (23.3)
8 (57.1)
6 (42.9)
0.069
Married
46 (76.7)
14 (30.4)
34 (69.6)
Diabetes:
Absent
30 (50)
7 (23.3)
23 (94.6)
0.032*
Present
30 (50)
15 (50)
15 (50)
Hypertension:
Absent
36 (60)
9 (25)
27 (75)
0.03*
Present
24 (40)
13 (54.2)
11 (45.8)
Hepatitis:
HbSAg positive
3 (5)
1 (33.3)
2 (66.7)
>0.999
HCV RNA positive
57 (95)
21 (36.8)
36 (63.2)
Portosystemic shunt:
Absent
22 (36.7)
1 (4.5)
21 (95.5)
<0.001**
Present
38 (63.3)
21 (55.3)
17 (44.7)
Ammonia level:
Normal
7 (11.7)
0 (0)
7 (100)
<0.001**
High
53 (88.3)
22 (41.5)
31 (58.5)
Table 3. Relation between presence of MHE and both age
patients
Parameters
Total
MHE
Present
Mean ± SD
Mean ± SD
49.82±8.39
53.55±5.12
Age (years)
12.38 ± 1.73
12.18 ± 1.37
Hemoglobin (g/dL)
6.8 ± 1.66
6.33 ± 1.85
TLC (103/mm3)
Platelet count (103/mm3) 205.75 ±44.77 182.36±32.99
42.34 ± 18.74
38.41 ± 20.43
ALT (U/L)
44.29 ± 18.52
39.41 ± 18.24
AST (U/L)
0.78 ± 0.21
0.76 ± 0.23
Total bilirubin (mg/dL)
3.82 ± 0.25
3.7 ± 0.24
Serum albumin (g/dL)
63.52 ±10.27
73.64 ± 4.89
Ammonia (mg/dL)
1.12 ± 0.18
1.24 ± 0.21
INR
*p<0.05 is statistically significant
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OR (95% CI)

0.28(0.08-0.97)

4.57(1.45-14.39)
2.31 (0.79 – 6.76)

3.05(0.89 -10.35)

3.29(1.08 - 9.95)

3.55(1.18-10.67)

1.17(0.1- 13.66)

25.94(3.16
213.02)

-

0

and laboratory data of the studied

Absent
Mean ± SD
47.66 ± 9.19
12.5 ± 1.91
7.08 ± 1.5
219.29±45.44
44.62 ± 17.57
47.12 ± 18.34
0.8 ± 0.2
3.89 ± 0.23
57.66 ± 7.64
1.04 ± 0.09

Test
t

p

2.761
-0.684
-1.718
-3.332
-1.242
-1.572
-0.719
-3.067
4.193
8.801

0.008*
0.497
0.091
0.002*
0.219
0.121
0.475
0.003*
<0.001**
<0.001**
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Table 4. Logistic regression of factors associated with MHE among the studied patients
β
p
Odds Ratio
95% Confidence interval
Lower
Upper
1.401
0.02*
4.060
1.243
13.257
Ammonia
(mg/dL)
DISCUSSION
The current study revealed high prevalence
of MHE among compensated cirrhosis
patients (36.7 percent). Different studies
found that the prevalence of MHE in cirrhosis
patients was measured at 18.2%, 30, 55.8%
and 84% [18-21] based on the diagnostic
criteria and the population being tested. The
prevalence of MHE in patients with cirrhosis
was 44.0 percent, lower than that found by
Maric et al., who reported 80 percent
frequency in the same patient type, according
to the results of this study [22]. This
discrepancy in the number of MHE patients
can be attributed to variation in patient
selection criteria, disparity in diagnostic
criteria and variations of the measures used.
The prevalence of MHE in a previous
Japanese study was 28.6% [23]. Former
Egyptian studies reported that MHE was
prevalent in 25.7 and 47% of patients with
cirrhosis [24-25]. There were no differences
between the MHE-positive and MHEnegative patients in clinical features. Elevated
levels of ammonia in plasma (P=0.034)
among biochemical parameters. Nevertheless,
univariate and multivariate analysis showed
the degree of ammonia (odds ratio, 1.023 and
1.031, respectively; confidence interval of 95
percent of coefficient figures, 1.005-1.041
and 1.006-1.058, respectively) was the only
important independent indicator for detecting
MHE [23].
In Awad et al., study, In terms of age and
marital status, there was a statistically
significant difference between normal and
abnormal hepatic encephalopathy scores.
There were, however, no statistically
significant differences in the other descriptive
data between the two groups [24]. This is in
agreement with former study [26] Who has
reported
that
age
can
influence
neuropsychological output in MHE patients.
Many studies have shown no effect of age or
gender on MHE diagnosis [27].
Mahmoud A.,et al…
Published by Arab Journals Platform, 2021

Throughout our research we found that in
patients with MHE the ammonia level was
significantly higher. Such reports correlated
with Gad et al. [25] and Awad et al. [24].
Nonetheless, these findings were not in line
with Li et al. [28] who stated that MHE was
not associated with levels of venous ammonia
which can be clarified in patients with MHE,
The blood-brain barrier may be breached,
allowing ammonia to spread more freely
across the blood-brain barrier into the brain,
as the concentration of venous ammonia in
MHE patients may be similar to those without
MHE [30].
In the study by Awad et al., [24], they
reported that smoking and increasing age,
were risk factors for MHE. Gad et al.,[25]
who identified smoking as a significant risk
factor for MHE, too. Our result showed nonsignificant relation between presence of MHE
and either education, marital status, AT, AST
levels, total bilirubin yet with significant
relation between it and both INR and
ammonia level in agreement with the study by
Abdelrahman et al., [30]
Hyperammonemia has been classically
known to be the the main trigger of HE.
Nonetheless,
the
role
of
systemic
inflammatory response has increased in
importance in recent years as synergistic
factors, particularly TNFα andIL-6. Both are
spurred by resistance to insulin and DM. In
addition, DM may increase constipation risk
for HE and increased glutaminase activity.
Nonetheless, the safest and most effective
treatment for diabetes in cirrhotics is still
uncertain. Strict regulation of glucose in
cirrhotic patients in general, especially in
high-risk conditions of insulin resistance such
as T2DM and obesity, would therefore be
advised to avoid HE [18]. In an earlier study
of the social consequences of cognitive
disorders in minimal hepatic encephalopathy
(MHE) of 60 patients with chronic genotype 1
hepatitis C and the possibilities of their L85 | P a g e
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ornithine-L-aspartate (LOLA, Hepa-Merz)
pharmacological
adjustment.
Fractional
therapy of L-ornithine-L-aspartate (LOLA)
results in a reduction in ammonium ion
content in the blood and, subsequently, an
increase in psychometric test results and a
decrease in traffic code violation frequency.
The outcome obtained will affect the
reduction in the accident rate [31].
In our study, spontaneous Porto systemic
shunts were detected in 65% of patients (39
cases) by doppler ultrasound at different sites
in contrast to 35% (21 cases) of absent shunts
at any site. In comparison to the other similar
studies, Simón-Talero et al., [32] found that
the prevalence of these shunts is About 60%
in patients with cirrhosis.
Although, comparing to another large,
multicentric, international study Bossen et al.,
[33] found that the prevalence of these shunts
were about 56% in cirrhotics.
Nicoletti et al., [35] found that 18% of
non-cirrhotic portal hypertension had at least
one documented episode of overt hepatic
encephalopoathy in comparison to only 14%
of cirrhotics. The presence of large
portosystemic shunts was the only factor
significantly
correlated
to
cognitive
impairment
in
non-cirrhotic
portal
hypertensive patients.
On the other hand, our study shows
elevated ammonia level in a significant
percentage of our patients 88.3% in
comparison to 11.6% of normal ammonia
level, with mean ammonia level 63.5±10.2.
Concerning
minimal
hepatic
encephalopathy per say, our results is
comparable to Zhang Y et al., [35] results,
who found that ammonia level was
significantly high in patients with MHE .
Although our results go with what has been
reported by Iwasa et al., [36] who found that
hyperammonemia is a major contributing
factor to the development of covert hepatic
encephalopathy (MHE&1st grade of overt
HE) in cirrhotic patients.
Being cross sectional study, it only
suggests risk factors but cannot really prove
causal relation or time needed for any risk to
head the MHE. We recommend large scale
prospective studies to identify risk factors of
Mahmoud A.,et al…
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MHE.
CONCLUSION
MHE is a prevalent condition among patients
with compensated cirrhosis with high
ammonia level is a strong risk factors for its
development.
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